The upregulation of AKT-activity by TRAIL-R4 knockdown strongly indicates that this receptor might act as an endogenous negative regulator of this cancer cell-autonomous malignancy-promoting TRAIL-R signaling pathway. This evidence concerns the gene AKT1 and cancer.